Skip to content
Assyro AI
US FDA source recordWL · Warning Letter

Ketacyn Pharmaceuticals / www.ketacynpharma.com — FDA Warning Letter

Issued to Ketacyn Pharmaceuticals / www.ketacynpharma.com. Serious post-market compliance violation.

Issued

June 23, 2026

Product

Unapproved New Drugs/Misbranded

Company

Ketacyn Pharmaceuticals / www.ketacynpharma.com

Review center

CDER

Stage

Final Decision

Read source documentView similar WL records

Assyro regulatory brief

Free

Why did Ketacyn Pharmaceuticals / www.ketacynpharma.com receive an FDA warning letter?

Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.

Verify in source

Source facts

FDA issued a warning letter to Ketacyn Pharmaceuticals / www.ketacynpharma.com concerning Unapproved New Drugs/Misbranded. Deterministic source-metadata screening identifies discussion of Labeling, claims, and misbranding. Topic matches are navigation aids, not a legal conclusion; review the exact FDA web letter and any later response or closeout.

Key details in this letter

  • 1Subject: Unapproved New Drugs/Misbranded.
  • 2Issuing office: Center for Drug Evaluation and Research (CDER).
  • 3Labeling, claims, and misbranding: 1 source-text match.
  • 4No closeout letter was listed in the source metadata at refresh time.
Labeling, claims, and misbranding

Suggested next step

Review the exact FDA warning letter, cited violations, requested corrections, and any later response or closeout before assessing current status.

Open the document workspace

Built from structured FDA metadata and deterministic source-text signals. Topic matches are navigation aids, not legal or regulatory conclusions. Verify material decisions against the original FDA document.

FDAHTMLUpdated Jul 30, 2026

FDA source document

Read the full FDA warning letter

FDA publishes this warning letter as a web document.

Open the exact FDA source to read the complete letter and verify its current response or closeout status.

Open source on FDA.gov

Common questions about the Ketacyn Pharmaceuticals / www.ketacynpharma.com warning letter

What does this warning letter mean for Ketacyn Pharmaceuticals / www.ketacynpharma.com?

Serious post-market compliance violation. Public notice requiring prompt remediation. FDA issued this letter on June 23, 2026.

What happens after an FDA warning letter?

The firm is expected to respond in writing, normally within 15 working days, describing corrective actions and timelines. FDA verifies remediation — often through reinspection — and issues a closeout letter when violations are corrected. Unresolved warning letters can escalate to import alerts, seizure, or injunction.